Parabilis Targets 2027 Phase III Trial for Lead Cancer Candidate

Parabilis Therapeutics plans to initiate a Phase III, placebo-controlled trial for its lead candidate, zolucatetide, in the first half of 2027. The company intends to enroll approximately 150 patients with desmoid tumors. Parabilis is using its $1.1 billion cash position to fund the trial and expand development of its proprietary Helicon platform.

"The IPO proceeds allow the company to 'lean into the full potential of zolucatetide' and pursue multiple value-creating programs at once," said Matthai Mammen, Chief Executive of Parabilis, at the Morgan Stanley conference.

Clinical Performance and Trial Design

In early-stage dose-escalation trials involving 38 patients with desmoid tumors, zolucatetide demonstrated a 74% response rate. Patients in the study had a median treatment duration of nine months, according to a transcript from the Morgan Stanley conference.

The upcoming Phase III trial increases the scale for the drug candidate. By moving to a placebo-controlled design, Parabilis aims to generate the data required for potential regulatory submissions in the treatment of these locally aggressive, non-metastatic tumors.

Targeting Undruggable Proteins

Zolucatetide is built on the company's Helicon platform. This platform targets intracellular proteins that lack traditional binding pockets. In conventional drug development, many proteins are considered undruggable because their surfaces are too flat or featureless for small-molecule drugs to attach effectively.

Helicon technology uses a modular approach to identify and bind to these specific protein surfaces to modulate beta-catenin pathways. By targeting these pathways, the company seeks to inhibit the growth of tumors driven by aberrant protein interactions.

Financial Runway and Market Position

Parabilis currently holds approximately $1.1 billion in cash. The company expects this will provide sufficient financial runway to support operations and clinical development through 2030. This liquidity allows the firm to maintain its development timelines without the immediate need for additional capital raises.

As of the market close on September 18, 2026, shares of Parabilis (PBLS) were priced at $41.73, a 2.1% increase for the day. The company's current valuation reflects investor focus on the progression of its pipeline from early-stage clinical data to late-stage pivotal trials.